Evidence map›Paper›PMID 38962307›Full record

ArticleFrontiers in pharmacology2024

Development of radioiodine-labeled mequitazine for evaluation of hepatic CYP2D activity.

Asuka Mizutani, Masato Kobayashi, Kodai Nishi, Ken-Ichi Fujita, Kotaro Takahashi, Yuka Muranaka, Kakeru Sato, Masanori Kitamura, Chie Suzuki, Ryuichi Nishii and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Asuka MizutaniFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Masato KobayashiFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Kodai NishiDepartment of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Ken-Ichi FujitaDivision of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
Kotaro TakahashiDepartment of Radiologic Technology, National Cancer Center Hospital East, Kashiwa, Japan.
Yuka MuranakaDepartment of Radiological Technology, Faculty of Health Science, Juntendo University, Tokyo, Japan.
Kakeru SatoDivision of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Masanori KitamuraFaculty of Pharmaceutical Sciences, Matsuyama University, Matsuyama, Japan.
Chie SuzukiPreeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Ryuichi NishiiDepartment of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Naoto ShikanoDepartment of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ibaraki, Japan.
Yasuhiro MagataPreeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yasushi IshidaDepartment of Psychiatry, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Munetaka KunishimaFaculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
Kazuki FukuchiDivision of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
Keiichi KawaiFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CYP2Ddrug-metabolizing enzymeindividualized medicinemequitazinewhole-body imaging

Identifiers

PMID38962307
PMCPMC11219936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.